Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine

Overview of attention for article published in Frontiers in Neurology, January 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 1 news story.

A combination of onabotulinumtoxinA and a calcitonin gene-related peptide monoclonal antibody appears effective and safe in…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.